İsmail Sarı1, Hatice Ökten2, Çağdaş Aktan3, Esra Cihan4. 1. Niğde Omer Halisdemir University, Faculty of Medicine, Department of Medical Biochemistry, Niğde, Turkey. 2. Beykent University, Faculty of Medicine, Department of Medical Biochemistry, Istanbul, Turkey. 3. Beykent University, Faculty of Medicine, Department of Medical Biology, Istanbul, Turkey. 4. Niğde Omer Halisdemir University, Faculty of Medicine, Department of Obstetrics and Gynaecology, Niğde, Turkey.
Abstract
BACKGROUND: The epoxyeicosatrienoic acids (EETs) have antihypertensive, anti-inflammatory, and organ protective properties and their circulation levels are related to hypertension, diabetes mellitus, cardiovascular diseases, and preeclampsia. Soluble epoxide hydrolase (sEH) catalyses the degradation of EETs to less biologically active dihydroxyeicosatrienoic acids. Here, we sequenced the promoter region of EPHX2 to investigate the association between promoter sequence alterations that we thought to affect the expression levels of the enzyme and preeclampsia (PE). METHODS: Nucleotide sequencing of the promoter region of the EPHX2, spanning from position -671 to +30, was performed on 100 pregnant women with PE and, 20 or more weeks pregnant normotensive, healthy women (n=100). RESULTS: Pregnant women who carry rs4149235, rs4149232, rs73227309, and rs62504268 polymorphisms have 4.4, 2.4, 2.3, and 2.8 times significantly increased risk of PE, respectively. CCGG (OR: 3.11; 95% CI: 1.12-8.62) and CCCA (OR: 0.45; 95% CI: 0.36-0.55) haplotypes were associated with an increased and decreased risk of PE, respectively. CONCLUSIONS: Four SNPs (rs4149232, rs4149235, rs73227309, and rs62504268) in the promoter region of the EPHX2, and CCGG and CCCA haplotypes of these 4 SNPs were significantly associated with PE. These SNPs in the promoter region may affect sEH expression and thus enzyme activity and may play a role in PE pathogenesis by causing individual differences in EET levels. However, future studies are needed to confirm our findings and examine the effect of these SNPs on the sEH expression and/or enzyme activity. 2020 İsmail Sarı, Hatice Ökten, Çağdaş Aktan, Esra Cihan, published by CEON/CEES.
BACKGROUND: The epoxyeicosatrienoic acids (EETs) have antihypertensive, anti-inflammatory, and organ protective properties and their circulation levels are related to hypertension, diabetes mellitus, cardiovascular diseases, and preeclampsia. Soluble epoxide hydrolase (sEH) catalyses the degradation of EETs to less biologically active dihydroxyeicosatrienoic acids. Here, we sequenced the promoter region of EPHX2 to investigate the association between promoter sequence alterations that we thought to affect the expression levels of the enzyme and preeclampsia (PE). METHODS: Nucleotide sequencing of the promoter region of the EPHX2, spanning from position -671 to +30, was performed on 100 pregnant women with PE and, 20 or more weeks pregnant normotensive, healthy women (n=100). RESULTS: Pregnant women who carry rs4149235, rs4149232, rs73227309, and rs62504268 polymorphisms have 4.4, 2.4, 2.3, and 2.8 times significantly increased risk of PE, respectively. CCGG (OR: 3.11; 95% CI: 1.12-8.62) and CCCA (OR: 0.45; 95% CI: 0.36-0.55) haplotypes were associated with an increased and decreased risk of PE, respectively. CONCLUSIONS: Four SNPs (rs4149232, rs4149235, rs73227309, and rs62504268) in the promoter region of the EPHX2, and CCGG and CCCA haplotypes of these 4 SNPs were significantly associated with PE. These SNPs in the promoter region may affect sEH expression and thus enzyme activity and may play a role in PE pathogenesis by causing individual differences in EET levels. However, future studies are needed to confirm our findings and examine the effect of these SNPs on the sEH expression and/or enzyme activity. 2020 İsmail Sarı, Hatice Ökten, Çağdaş Aktan, Esra Cihan, published by CEON/CEES.
Authors: Craig R Lee; Kari E North; Molly S Bray; Myriam Fornage; John M Seubert; John W Newman; Bruce D Hammock; David J Couper; Gerardo Heiss; Darryl C Zeldin Journal: Hum Mol Genet Date: 2006-04-04 Impact factor: 6.150
Authors: Houli Jiang; John C McGiff; Cristiano Fava; Gabriella Amen; Elisa Nesta; Giovanni Zanconato; John Quilley; Pietro Minuz Journal: Am J Hypertens Date: 2012-12-28 Impact factor: 2.689
Authors: Florian Herse; Babbette Lamarca; Carl A Hubel; Tea Kaartokallio; A Inkeri Lokki; Eeva Ekholm; Hannele Laivuori; Martin Gauster; Berthold Huppertz; Meryam Sugulle; Michael J Ryan; Sarah Novotny; Justin Brewer; Joon-Keun Park; Michael Kacik; Joachim Hoyer; Stefan Verlohren; Gerd Wallukat; Michael Rothe; Friedrich C Luft; Dominik N Muller; Wolf-Hagen Schunck; Anne C Staff; Ralf Dechend Journal: Circulation Date: 2012-11-15 Impact factor: 29.690
Authors: Babbette LaMarca; Denise C Cornelius; Ashlyn C Harmon; Lorena M Amaral; Mark W Cunningham; Jessica L Faulkner; Kedra Wallace Journal: Am J Physiol Regul Integr Comp Physiol Date: 2016-04-20 Impact factor: 3.619
Authors: Mandi J Corenblum; Vance E Wise; Katrin Georgi; Bruce D Hammock; Peter A Doris; Myriam Fornage Journal: Hypertension Date: 2007-12-17 Impact factor: 10.190